Gadoxetate disodium

Drug Profile

Gadoxetate disodium

Alternative Names: EOB Primovist; Eovist; gadolinium EOB DTPA; gadoxetic acid; Gd-EOB-DTPA; Primovist; ZK 139834

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Massachusetts General Hospital
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Acetic acids; Gadolinium-containing contrast agents; Organometallic compounds; Polyamines; Small molecules
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver disorders

Most Recent Events

  • 01 Apr 2017 Discontinued - Phase-III for Liver disorders (Diagnosis, In infants) in USA (IV), because not listed on Bayer pipeline, April 2017
  • 15 Dec 2016 Biomarkers information updated
  • 01 Feb 2015 Phase-III clinical trials in Liver disorders (Diagnosis, In infants) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top